title: Chemotherapeutic inhibition of erb-B2 oncogene expression on a non-small-cell cancer line (NSCLC-N6) by marine substances.
abstract: The inhibitory effect of natural substances of marine origin on the erb-B2 oncogene of a human NSCLC-N6 line was demonstrated in vitro by simultaneous study of the expression of the gene and its product, using respectively an erb-B2 specific probe and an anti-c-erb-B2 polyclonal antibody. Preliminary results indicate inhibition ranging from 17-77% of oncogene expression and from 77-90% of product expression. The fact that substances of this type, with different chemical structures, have the common ability to induce terminal differentiation in an experimental model after irreversible blockade in G1 phase suggests a relationship between the inhibition of certain oncogenes and terminal differentiation.
authors.affiliation: SMAB (Substances Marines à Activité Biologique), Faculté de Pharmacie, B.P., Nantes.
authors.forename: C
authors.initials: C
authors.lastname: Roussakis
authors.forename: J
authors.initials: J
authors.lastname: Charrier
authors.forename: D
authors.initials: D
authors.lastname: Riou
authors.forename: J F
authors.initials: JF
authors.lastname: Biard
authors.forename: C
authors.initials: C
authors.lastname: Malochet
authors.forename: K
authors.initials: K
authors.lastname: Meflah
authors.forename: J F
authors.initials: JF
authors.lastname: Verbist
mesh_terms: D000081:Acetamides; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics*; D002454:Cell Differentiation / Q000187:drug effects; D004224:Diterpenes / Q000494:pharmacology; D066246:ErbB Receptors / Q000096:biosynthesis*; D004988:Ethers, Cyclic / Q000494:pharmacology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics*; D009857:Oncogenes / Q000187:drug effects*; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis*; D011714:Pyrans; D018719:Erb-b2 Receptor Tyrosine Kinases; D013141:Spiro Compounds; D013388:Succinimides / Q000494:pharmacology; D014407:Tumor Cells, Cultured
chemical_list: D000081:Acetamides; D000970:Antineoplastic Agents; D004224:Diterpenes; D066246:ErbB Receptors; D004988:Ethers, Cyclic; D011518:Proto-Oncogene Proteins; D011714:Pyrans; D018719:Erb-b2 Receptor Tyrosine Kinases; D013141:Spiro Compounds; D013388:Succinimides; C059975:bistratene A; C079664:dichlorolissoclimide; C079665:chlorolissoclimide; C085520:bistramide D